Semax

Semax | Peptide Complex

Nootropic

Semax is a synthetic heptapeptide analogue of the ACTH(4-7) fragment — Met-Glu-His-Phe-Pro-Gly-Pro — developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It retains the neurotrophic and cognitive properties of ACTH without adrenocortical stimulation. Semax is approved as a drug in Russia for stroke rehabilitation and cognitive impairment, and has been extensively studied for its neuroprotective, nootropic, and neurotrophin-modulating effects. It is considered one of the most potent peptide-based cognitive research compounds available.

• BDNF & NGF Upregulation — Semax strongly upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, supporting neuroplasticity, memory formation, and neuronal survival.

• Cognitive Performance — Research indicates Semax enhances working memory, attention, and executive function, with studies in both healthy subjects and cognitively impaired models showing measurable improvements in processing speed and retention.

• Neuroprotection & Stroke Research — Approved for clinical use in Russia following stroke, Semax has demonstrated neuroprotective effects by reducing ischemic brain damage, oxidative stress, and excitotoxicity in neural tissue.

• Dopaminergic & Serotonergic Modulation — Studies suggest Semax modulates dopamine and serotonin signaling in the prefrontal cortex and limbic system, contributing to mood stabilization, motivation, and stress resilience.

• Immune & Inflammatory Regulation — Research has identified anti-inflammatory properties in Semax, including downregulation of inflammatory gene expression in brain tissue following injury or chronic stress.